Ananília Medeiros Gomes da Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ananília Medeiros Gomes da Silva has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Vivian Nogueira Silbiger
Affiliations Translational Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada, Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
6 shared publications - André Ducati Luchessi
Federal University of Rio Grande do Norte
3 shared publications - Adriana Augusto de Rezende
Health Sciences Postgraduate Program, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil; Department of Clinical and Toxicological Analyses, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
2 shared publications Jéssica Nayara Góes de Araújo
Department of Clinical Analysis and Toxicology, Federal University of Rio Grande do Norte, Natal, RN, Brazil
2 shared publications- Karla Simone Costa de Souza
Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal, Brazil
2 shared publications Marina Sampaio Cruz
Department of Clinical and Toxicology Analysis, Federal University of Rio Grande do Norte, Natal, RN, Brazil
2 shared publications
Latest Publications
- Open Access
- 7 January 2026
- Published by Springer Nature in Genome Medicine
- Vol. 18 (1) , 2
DNA methylation analysis of NOTCH1 variants reveals the first episignature for non-syndromic congenital heart defects
Background: Congenital heart defects (CHDs) are the most common malformation amongst newborns, with a prevalence of approximately 0.8–2%. The etiology of CHD is highly complex and can be linked to genetic and nongenetic factors. The molecular basis remains partially unclear, and only a minority of patients can be assigned to clear monogenic causes. Methods: Here we analyzed a cohort of 3907 CHD cases and population-matched controls using exome sequencing. In addition, we employed epigenetic profiling on a subset of cases that harbored rare NOTCH1 variants. Results: We identified 24 pathogenic or likely pathogenic single nucleotide variants (SNVs) in NOTCH1 in our exome cohort, as well as a further 15 variants of uncertain significance (VUS) likely to have a deleterious effect. Although the cardiac phenotypes showed some heterogeneity, non-syndromic Tetralogy of Fallot (ToF) and related malformations were the most frequent finding in 56% (22/39). In particular, missense variants altering cysteine residues involved in forming disulfide bridges were identified, specifically in TOF patients. Altogether, NOTCH1 -haploinsufficiency represented the most common monogenic cause in our cohort and accounted for an estimated 1% of CHD cases. Combined with additional cases assembled through collaborations, we present 67 individuals with ultrarare variants affecting NOTCH1 . This prominent role of NOTCH1 calls for an accurate and accessible evaluation of variants. To this end we explored DNA methylation testing and successfully established a NOTCH1 -specific episignature. This signature also displays a robust specificity in relation to 99 other episignatures. Taken together, we found that truncating, splice-altering, as well as missense NOTCH1 variants, can generate a distinct DNAm episignature. Conclusions: We identified that NOTCH1 -haploinsufficiency variants represented the most common monogenic cause in our cohort and accounted for an estimated 1 % of CHD cases. Furthermore, we conclude that methylation profiling can contribute to (NOTCH1) variant interpretation and improve the diagnostic management of CHD patients. Lastly, we established a NOTCH1 -specific episignature, which represents the first non-syndromic signature, significantly extending the scope of patients that can benefit from methylation analysis.
- 7 January 2026
- Published by Springer Nature in Genome Medicine
- Vol. 18 (1) , 2
Open AccessDNA methylation analysis of NOTCH1 variants reveals the first episignature for non-syndromic congenital heart defects
Background: Congenital heart defects (CHDs) are the most common malformation amongst newborns, with a prevalence of approximately 0.8–2%. The etiology of CHD is highly complex and can be linked to genetic and nongenetic factors. The molecular basis remains partially unclear, and only a minority of patients can be assigned to clear monogenic causes. Methods: Here we analyzed a cohort of 3907 CHD cases and population-matched controls using exome sequencing. In addition, we employed epigenetic profiling on a subset of cases that harbored rare NOTCH1 variants. Results: We identified 24 pathogenic or likely pathogenic single nucleotide variants (SNVs) in NOTCH1 in our exome cohort, as well as a further 15 variants of uncertain significance (VUS) likely to have a deleterious effect. Although the cardiac phenotypes showed some heterogeneity, non-syndromic Tetralogy of Fallot (ToF) and related malformations were the most frequent finding in 56% (22/39). In particular, missense variants altering cysteine residues involved in forming disulfide bridges were identified, specifically in TOF patients. Altogether, NOTCH1 -haploinsufficiency represented the most common monogenic cause in our cohort and accounted for an estimated 1% of CHD cases. Combined with additional cases assembled through collaborations, we present 67 individuals with ultrarare variants affecting NOTCH1 . This prominent role of NOTCH1 calls for an accurate and accessible evaluation of variants. To this end we explored DNA methylation testing and successfully established a NOTCH1 -specific episignature. This signature also displays a robust specificity in relation to 99 other episignatures. Taken together, we found that truncating, splice-altering, as well as missense NOTCH1 variants, can generate a distinct DNAm episignature. Conclusions: We identified that NOTCH1 -haploinsufficiency variants represented the most common monogenic cause in our cohort and accounted for an estimated 1 % of CHD cases. Furthermore, we conclude that methylation profiling can contribute to (NOTCH1) variant interpretation and improve the diagnostic management of CHD patients. Lastly, we established a NOTCH1 -specific episignature, which represents the first non-syndromic signature, significantly extending the scope of patients that can benefit from methylation analysis.
- 4 January 2023
- Published by Springer Nature in Molecular Biology Reports
- Vol. 50 (3) , 2835-2845
Long non-coding RNA and circular RNA: new perspectives for molecular pathophysiology of atrial fibrillation
Many studies have demonstrated the association of atrial fibrillation (AF) with endogenous genetic regulatory mechanisms. These interactions could advance the understanding of the AF pathophysiological process, supporting the search for early biomarkers to improve diagnosis and disease monitoring. Among the endogenous genetic regulatory mechanisms, long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) have gained special attention, and studies have demonstrated their involvement in AF development and other AF-related diseases such as coronary artery disease and cardiomyopathy. This review describes the main experimental results reported by studies that analyzed the expression of lncRNAs and circRNAs in AF associated with miRNA or mRNA. The search was conducted in PubMed public database using the terms “lncRNA and atrial fibrillation” or “long ncRNA and atrial fibrillation” or “long non-coding RNA and atrial fibrillation” or “circular RNA and atrial fibrillation” or “circRNA and atrial fibrillation”. There was no overlapping of lncRNA or circRNA among the studies, attributed to the different sample types, methods, species, and patient classification evaluated in these studies. Although the regulatory mechanisms in which these molecules are involved are not yet well understood, the studies analyzed show their importance in the pathophysiological process of AF, supporting the idea that lncRNAs and circRNAs are involved in miRNA or mRNA regulation in the molecular mechanism of this disease.
- 4 January 2023
- Published by Springer Nature in Molecular Biology Reports
- Vol. 50 (3) , 2835-2845
Long non-coding RNA and circular RNA: new perspectives for molecular pathophysiology of atrial fibrillation
Many studies have demonstrated the association of atrial fibrillation (AF) with endogenous genetic regulatory mechanisms. These interactions could advance the understanding of the AF pathophysiological process, supporting the search for early biomarkers to improve diagnosis and disease monitoring. Among the endogenous genetic regulatory mechanisms, long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) have gained special attention, and studies have demonstrated their involvement in AF development and other AF-related diseases such as coronary artery disease and cardiomyopathy. This review describes the main experimental results reported by studies that analyzed the expression of lncRNAs and circRNAs in AF associated with miRNA or mRNA. The search was conducted in PubMed public database using the terms “lncRNA and atrial fibrillation” or “long ncRNA and atrial fibrillation” or “long non-coding RNA and atrial fibrillation” or “circular RNA and atrial fibrillation” or “circRNA and atrial fibrillation”. There was no overlapping of lncRNA or circRNA among the studies, attributed to the different sample types, methods, species, and patient classification evaluated in these studies. Although the regulatory mechanisms in which these molecules are involved are not yet well understood, the studies analyzed show their importance in the pathophysiological process of AF, supporting the idea that lncRNAs and circRNAs are involved in miRNA or mRNA regulation in the molecular mechanism of this disease.
- 28 June 2019
- Published by Springer Nature in Heart Failure Reviews
- Vol. 25 (2) , 321-329
miRNAs emerge as circulating biomarkers of post-myocardial infarction heart failure
Heart failure (HF) is a clinical syndrome that involves structural changes in the heart, leading to a decrease in cardiac output, mainly caused by myocardial infarction (MI), which is the most common form of cardiovascular disease worldwide. Clinical evaluation remains the most accurate diagnostic method for ischemic HF, since the known biomarkers have high cost, are difficult to use for early diagnosis, and have low specificity. This often leads to late diagnosis since only ~ 25% symptoms of HF appear after MI. Studies suggest that small non-coding RNAs (miRNAs) play an important role in the regulation of this pathophysiological process and are, therefore, important targets in the discovery of non-invasive biomarkers for HF. Thus, the aim of this review was to identify circulating miRNAs (plasma, serum, and whole blood) described for post-MI HF patients. This review covered 19 experimental studies on humans, which investigated the relationship between circulating miRNAs and the development, monitoring, or prognosis of ischemic HF. This analysis was aimed at proposing potential targets for HF and the future application of miRNAs as HF biomarkers.
- 28 June 2019
- Published by Springer Nature in Heart Failure Reviews
- Vol. 25 (2) , 321-329
miRNAs emerge as circulating biomarkers of post-myocardial infarction heart failure
Heart failure (HF) is a clinical syndrome that involves structural changes in the heart, leading to a decrease in cardiac output, mainly caused by myocardial infarction (MI), which is the most common form of cardiovascular disease worldwide. Clinical evaluation remains the most accurate diagnostic method for ischemic HF, since the known biomarkers have high cost, are difficult to use for early diagnosis, and have low specificity. This often leads to late diagnosis since only ~ 25% symptoms of HF appear after MI. Studies suggest that small non-coding RNAs (miRNAs) play an important role in the regulation of this pathophysiological process and are, therefore, important targets in the discovery of non-invasive biomarkers for HF. Thus, the aim of this review was to identify circulating miRNAs (plasma, serum, and whole blood) described for post-MI HF patients. This review covered 19 experimental studies on humans, which investigated the relationship between circulating miRNAs and the development, monitoring, or prognosis of ischemic HF. This analysis was aimed at proposing potential targets for HF and the future application of miRNAs as HF biomarkers.
- 20 April 2018
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 29 (8) , 1159-1166
Circulating miRNAs in acute new‐onset atrial fibrillation and their target mRNA network
Background: MicroRNAs (miRNAs) are involved in the pathogenesis of atrial fibrillation (AF), acting on development and progression. Our pilot study investigated the expression of six miRNAs and their miRNA–mRNA interactions in patients with acute new‐onset AF, well‐controlled AF, and normal sinus rhythm (controls).Methods and results: Plasma of acute new‐onset AF patients (n = 5) was collected in the emergency room when patients presented with irregular and fast‐atrial fibrillation rhythm. Samples from well‐controlled AF (n = 16) and control (n = 15) patients were collected during medical appointments following an ECG. Expression of miR‐21, miR‐133a, miR‐133b, miR‐150, miR‐328, and miR‐499 was analyzed by real‐time PCR. Ingenuity Pathway Analysis and the TargetScan database identified the top 30 mRNA targets of these miRNA, seeking the miRNA–mRNA interactions in cardiovascular process. Increased expression of miR‐133b (1.4‐fold), miR‐328 (2.0‐fold), and miR‐499 (2.3‐fold) was observed in patients with acute new‐onset AF, compared with well‐controlled AF and control patients. Decreased expression of miR‐21 was seen in patients with well‐controlled AF compared to those with acute new‐onset AF and controls (0.6‐fold). The miRNA‐mRNA interaction demonstrated thatSMAD7andFASLGgenes were the targets of miR‐21, miR‐133b, and miR‐499 and were directly related to AF, being involved in apoptosis and fibrosis.Conclusion: The miRNAs had different expression profiles dependent on the AF condition, with higher expression in the acute new‐onset AF than well‐controlled AF. Clinically, this may contribute to an effective assessment for patients, leading to early detection of AF and monitoring to reduce the risk of other serious cardiovascular events.
- 20 April 2018
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 29 (8) , 1159-1166
Circulating miRNAs in acute new‐onset atrial fibrillation and their target mRNA network
Background: MicroRNAs (miRNAs) are involved in the pathogenesis of atrial fibrillation (AF), acting on development and progression. Our pilot study investigated the expression of six miRNAs and their miRNA–mRNA interactions in patients with acute new‐onset AF, well‐controlled AF, and normal sinus rhythm (controls).Methods and results: Plasma of acute new‐onset AF patients (n = 5) was collected in the emergency room when patients presented with irregular and fast‐atrial fibrillation rhythm. Samples from well‐controlled AF (n = 16) and control (n = 15) patients were collected during medical appointments following an ECG. Expression of miR‐21, miR‐133a, miR‐133b, miR‐150, miR‐328, and miR‐499 was analyzed by real‐time PCR. Ingenuity Pathway Analysis and the TargetScan database identified the top 30 mRNA targets of these miRNA, seeking the miRNA–mRNA interactions in cardiovascular process. Increased expression of miR‐133b (1.4‐fold), miR‐328 (2.0‐fold), and miR‐499 (2.3‐fold) was observed in patients with acute new‐onset AF, compared with well‐controlled AF and control patients. Decreased expression of miR‐21 was seen in patients with well‐controlled AF compared to those with acute new‐onset AF and controls (0.6‐fold). The miRNA‐mRNA interaction demonstrated thatSMAD7andFASLGgenes were the targets of miR‐21, miR‐133b, and miR‐499 and were directly related to AF, being involved in apoptosis and fibrosis.Conclusion: The miRNAs had different expression profiles dependent on the AF condition, with higher expression in the acute new‐onset AF than well‐controlled AF. Clinically, this may contribute to an effective assessment for patients, leading to early detection of AF and monitoring to reduce the risk of other serious cardiovascular events.
- Open Access
- 1 February 2018
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 53 (3)
Association between kidney function and Framingham risk score in an admixed population of Brazil
Chronic kidney disease (CKD) increases cardiovascular disease (CVD) risk development. However, the mechanisms of reduced kidney function with CVD risk are unclear. This study aimed to investigate the association between kidney function and Framingham risk score (FRS) in participants with traditional cardiovascular risk factors and normal estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m² in an admixed population of Brazil. The participants were divided into three groups according to FRS: low risk group with 0% to 20%. The eGFR was calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). Data from participants were collected by questionnaire, and blood and urine samples were collected to analyze biochemical markers. A total of 214 subjects aged 53±10 years old was collected. There were 77 individuals in low risk group, 59 in moderate risk group and 78 in high-risk group. Mean eGFRCKD-EPI was 89.39±15.05 mL/min/1.73 m² and 90.74±16.17 mL/min/1.73 m2 when race adjustment. The results indicated that there is an increasing the cardiovascular risk with a decreased of eGFR, conforming to a significant inverse correlation observed between eGFR and FRS with Spearman correlation (R²=-0.256, pCKD-EPI (pCKD-EPI with race adjustment (p=0.002) among risk groups. The data suggests that the reduction eGFR is associated with elevated FRS among Brazilian adults without CKD. Furthermore, the results suggest that race adjustment it’s not necessary in Brazilian population.
- 1 February 2018
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 53 (3)
Open AccessAssociation between kidney function and Framingham risk score in an admixed population of Brazil
Chronic kidney disease (CKD) increases cardiovascular disease (CVD) risk development. However, the mechanisms of reduced kidney function with CVD risk are unclear. This study aimed to investigate the association between kidney function and Framingham risk score (FRS) in participants with traditional cardiovascular risk factors and normal estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m² in an admixed population of Brazil. The participants were divided into three groups according to FRS: low risk group with 0% to 20%. The eGFR was calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). Data from participants were collected by questionnaire, and blood and urine samples were collected to analyze biochemical markers. A total of 214 subjects aged 53±10 years old was collected. There were 77 individuals in low risk group, 59 in moderate risk group and 78 in high-risk group. Mean eGFRCKD-EPI was 89.39±15.05 mL/min/1.73 m² and 90.74±16.17 mL/min/1.73 m2 when race adjustment. The results indicated that there is an increasing the cardiovascular risk with a decreased of eGFR, conforming to a significant inverse correlation observed between eGFR and FRS with Spearman correlation (R²=-0.256, pCKD-EPI (pCKD-EPI with race adjustment (p=0.002) among risk groups. The data suggests that the reduction eGFR is associated with elevated FRS among Brazilian adults without CKD. Furthermore, the results suggest that race adjustment it’s not necessary in Brazilian population.
- Open Access
- 25 November 2017
- Published by Springer Nature in BMC Medical Genetics
- Vol. 18 (1) , 1-9
A new panel of SNPs to assess thyroid carcinoma risk: a pilot study in a Brazilian admixture population
Thyroid cancer is a common malignant disease of the endocrine system with increasing incidence rates over the last few decades. In this study, we sought to analyze the possible association of 45 single nucleotide polymorphisms (SNPs) with thyroid cancer in a population from Rio Grande do Norte, Brazil. Based on histological analysis by a pathologist, 80 normal thyroid specimens of tissue adjacent to thyroid tumors were obtained from the biobank at the Laboratory of Pathology of Liga Norte Riograndense Contra o Câncer, Natal, RN. Patient samples were then genotyped using the MassARRAY platform (Sequenon, Inc) followed by statistical analysis employing the SNPassoc package in R program. The genotypic frequencies of all 45 SNPs obtained from the International HapMap Project database and based on data from the ancestral populations of European and African origin were used to compose the control study group. In our study, the following 9 SNPs showed significant differences in their frequency when comparing the study and control groups: rs3744962, rs258107, rs1461855, rs4075022, rs9943744, rs4075570, rs2356508, rs17485896, and rs2651339. Furthermore, the SNPs rs374492 C/T and rs258107 C/T were associated with a relative risk for thyroid carcinoma of 3.78 (p = 6.27 × 10e−5) and 2.91 (p = 8.27 × 10e−5), respectively, after Bonferroni’s correction for multiple comparisons. These nine polymorphisms could be potential biomarkers of predisposition to thyroid carcinoma in the population from Rio Grande do Norte. However, complementary studies including a control group with samples obtained from healthy subjects in Rio Grande do Norte state, should be conducted to confirm these results.
- 25 November 2017
- Published by Springer Nature in BMC Medical Genetics
- Vol. 18 (1) , 1-9
Open AccessA new panel of SNPs to assess thyroid carcinoma risk: a pilot study in a Brazilian admixture population
Thyroid cancer is a common malignant disease of the endocrine system with increasing incidence rates over the last few decades. In this study, we sought to analyze the possible association of 45 single nucleotide polymorphisms (SNPs) with thyroid cancer in a population from Rio Grande do Norte, Brazil. Based on histological analysis by a pathologist, 80 normal thyroid specimens of tissue adjacent to thyroid tumors were obtained from the biobank at the Laboratory of Pathology of Liga Norte Riograndense Contra o Câncer, Natal, RN. Patient samples were then genotyped using the MassARRAY platform (Sequenon, Inc) followed by statistical analysis employing the SNPassoc package in R program. The genotypic frequencies of all 45 SNPs obtained from the International HapMap Project database and based on data from the ancestral populations of European and African origin were used to compose the control study group. In our study, the following 9 SNPs showed significant differences in their frequency when comparing the study and control groups: rs3744962, rs258107, rs1461855, rs4075022, rs9943744, rs4075570, rs2356508, rs17485896, and rs2651339. Furthermore, the SNPs rs374492 C/T and rs258107 C/T were associated with a relative risk for thyroid carcinoma of 3.78 (p = 6.27 × 10e−5) and 2.91 (p = 8.27 × 10e−5), respectively, after Bonferroni’s correction for multiple comparisons. These nine polymorphisms could be potential biomarkers of predisposition to thyroid carcinoma in the population from Rio Grande do Norte. However, complementary studies including a control group with samples obtained from healthy subjects in Rio Grande do Norte state, should be conducted to confirm these results.
- Open Access
- 1 January 2017
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-7
Circulating MicroRNAs as Potential Biomarkers of Atrial Fibrillation
Atrial fibrillation (AF) is the most common supraventricular arrhythmia in the population. MicroRNAs (small endogenous noncoding RNAs) are attractive candidates as biomarkers for AF, especially considering that miRNAs are stable and are detected within easily accessible biofluids such as blood. In this review, we selected twelve studies (2012 to 2016) that were classified according to the sample type. We aimed to provide an overview of the role of circulating miRNAs in AF and to discuss the variability of the results, seeking to improve the perspective of the use of miRNAs as potential noninvasive biomarkers for this heart disease.
- 1 January 2017
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-7
Open AccessCirculating MicroRNAs as Potential Biomarkers of Atrial Fibrillation
Atrial fibrillation (AF) is the most common supraventricular arrhythmia in the population. MicroRNAs (small endogenous noncoding RNAs) are attractive candidates as biomarkers for AF, especially considering that miRNAs are stable and are detected within easily accessible biofluids such as blood. In this review, we selected twelve studies (2012 to 2016) that were classified according to the sample type. We aimed to provide an overview of the role of circulating miRNAs in AF and to discuss the variability of the results, seeking to improve the perspective of the use of miRNAs as potential noninvasive biomarkers for this heart disease.
- 19 August 2014
- Published by Taylor & Francis in Biomarkers
- Vol. 19 (8) , 631-636
miRNAs as biomarkers of atrial fibrillation
Atrial fibrillation (AF) is a highly prevalent arrhythmia with pronounced morbidity and mortality. Genetics analysis has established electrophysiological substrates, which determine individual vulnerability to AF occurrence and maintenance. MicroRNAs (miRNAs) found in virtually all organisms function as negative regulators of protein-coding genes. Several studies have suggested a role for miRNAs in the regulation of cardiac excitability and arrhythmogenesis. This review is based on 18 studies conducted between 2009 and 2013 to investigate the association of miRNAs with AF. miRNAs are discussed here as candidate biomarkers for AF in blood and cardiac tissues and as potential targets for AF therapy.
- 19 August 2014
- Published by Taylor & Francis in Biomarkers
- Vol. 19 (8) , 631-636
miRNAs as biomarkers of atrial fibrillation
Atrial fibrillation (AF) is a highly prevalent arrhythmia with pronounced morbidity and mortality. Genetics analysis has established electrophysiological substrates, which determine individual vulnerability to AF occurrence and maintenance. MicroRNAs (miRNAs) found in virtually all organisms function as negative regulators of protein-coding genes. Several studies have suggested a role for miRNAs in the regulation of cardiac excitability and arrhythmogenesis. This review is based on 18 studies conducted between 2009 and 2013 to investigate the association of miRNAs with AF. miRNAs are discussed here as candidate biomarkers for AF in blood and cardiac tissues and as potential targets for AF therapy.